Diet therapy | Exercise | Metformin Immediate Release Maximum Tolerated Dose Stable | Metformin Extended Release Maximum Tolerated Dose Stable | Combined Modality Therapy | Metformin | Sulfonylureas | Meglitinide
Item
have been treated with diet and exercise and a stable, maximally tolerated dose of immediate-release or extended-release metformin, or the combination of metformin (any dosage) with sulfonylurea/meglitinides for at least 3 months prior to study start
boolean
C0012159 (UMLS CUI [1])
C0015259 (UMLS CUI [2])
C0025598 (UMLS CUI [3,1])
C1708470 (UMLS CUI [3,2])
C0752079 (UMLS CUI [3,3])
C0205360 (UMLS CUI [3,4])
C0025598 (UMLS CUI [4,1])
C1707968 (UMLS CUI [4,2])
C0752079 (UMLS CUI [4,3])
C0205360 (UMLS CUI [4,4])
C0009429 (UMLS CUI [5])
C0025598 (UMLS CUI [6])
C0038766 (UMLS CUI [7])
C0065880 (UMLS CUI [8])
Absence Thiazolidinediones chronic | Absence alpha-Glucosidase Inhibitors chronic | Absence Insulin Formulation chronic | Exception Emergency Situation
Item
have not received thiazolidinediones, or alpha-glucosidase inhibitors for longer than 2 weeks within 3 months prior to study start, and have not received any insulin formulation for more than 14 days (other than in emergency situations) and within 14 days prior to study start
boolean
C0332197 (UMLS CUI [1,1])
C1257987 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0332197 (UMLS CUI [2,1])
C1299007 (UMLS CUI [2,2])
C0205191 (UMLS CUI [2,3])
C0332197 (UMLS CUI [3,1])
C0021641 (UMLS CUI [3,2])
C0524527 (UMLS CUI [3,3])
C0205191 (UMLS CUI [3,4])
C1705847 (UMLS CUI [4,1])
C0013956 (UMLS CUI [4,2])
Hemoglobin A1c measurement
Item
have an hba1c between 6.5% and 10.0%, inclusive
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
have a body mass index (bmi) between 25 kg/m^2 and 40 kg/m^2, inclusive
boolean
C1305855 (UMLS CUI [1])
Diabetes Mellitus, Insulin-Dependent | Latent Autoimmune Diabetes in Adults
Item
have type 1 diabetes or known latent autoimmune diabetes in adults
boolean
C0011854 (UMLS CUI [1])
C1739108 (UMLS CUI [2])
Systemic Glucocorticoids chronic | Exception Pharmaceutical Preparations Topical | Exception Inhalation Drug Administration | Systemic Glucocorticoids Recently
Item
are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks prior to study start
boolean
C3540777 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C1710439 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0001559 (UMLS CUI [3,2])
C3540777 (UMLS CUI [4,1])
C0332185 (UMLS CUI [4,2])
Pharmacotherapy Gastrointestinal Disease | Pharmaceutical Preparations Affecting Gastrointestinal Motility | Metoclopramide | Cisapride | Macrolide Antibiotics chronic
Item
are receiving treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility (e.g., metoclopramide, cisapride, and chronic macrolide antibiotics)
boolean
C0013216 (UMLS CUI [1,1])
C0017178 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0017184 (UMLS CUI [2,3])
C0025853 (UMLS CUI [3])
C0072916 (UMLS CUI [4])
C0003240 (UMLS CUI [5,1])
C0205191 (UMLS CUI [5,2])
Weight-Loss Agents
Item
have used any prescription drug to promote weight loss within 3 months prior to study start
boolean
C0376606 (UMLS CUI [1])
Pharmaceutical Preparation Without Approval
Item
have received treatment within 30 days prior to study start with a drug that has not received regulatory approval for any indication at the time of study entry
boolean
C0013227 (UMLS CUI [1,1])
C0332288 (UMLS CUI [1,2])
C0162696 (UMLS CUI [1,3])
Study Subject Participation Status | exenatide | GLP-1 analogues
Item
have previously completed or withdrawn from this study or any other study investigating exenatide or glp-1 analogs
boolean
C2348568 (UMLS CUI [1])
C0167117 (UMLS CUI [2])
C4301632 (UMLS CUI [3])